Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 1665 - 1672 of 12026 results
Pfizer/Seagen And What May Follow
May 12, 2023| News
Form I-9 Requirement Flexibility Ending July 31, 2023
May 12, 2023| Alert| Viewpoint
Heightened Risk for Banks as Account Fees Land on “Junk Fee” Agenda
May 11, 2023| Blog| Viewpoint
Nothing for free – the real costs of ChatGPT
May 11, 2023| Blog| Viewpoint
EXCLUSIVE RIGHTS: Intellectual Property — Avoiding Pitfalls: IP “Dos and Don’ts” for High-Tech Start-Ups
May 11, 2023| Podcast| Viewpoint
New York Joins Other States with Health Care Transaction Review Laws
May 11, 2023| Blog| Viewpoint
Making Bacon Still Requires a Significant Contribution for Joint Inventorship
May 10, 2023| Blog| Viewpoint
Feds Bring 18 Charges in Covid Crackdown, Lab Implicated
May 10, 2023| News
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|